Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.51 USD | -1.18% | -15.20% | -23.12% |
04-24 | Gain Therapeutics, Inc. Announces Positive Results from the Single Ascending Dose Part of the Phase 1 Clinical Trial of GT-02287 | CI |
04-08 | Gain Therapeutics Names Gene Mack as CFO | MT |
Sales 2024 * | 666K 910K | Sales 2025 * | 144K 197K | Capitalization | 45.31M 61.94M |
---|---|---|---|---|---|
Net income 2024 * | -21M -28.71M | Net income 2025 * | -28M -38.28M | EV / Sales 2024 * | 68 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 315 x |
P/E ratio 2024 * |
-2.19
x | P/E ratio 2025 * |
-2.13
x | Employees | 31 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.25% |
1 day | -1.18% | ||
1 week | -15.20% | ||
Current month | -14.33% | ||
1 month | -25.30% | ||
3 months | -50.20% | ||
6 months | -8.39% | ||
Current year | -23.12% |
Managers | Title | Age | Since |
---|---|---|---|
Matthias Alder
CEO | Chief Executive Officer | 59 | 21-10-18 |
Eric Richman
BRD | Director/Board Member | 63 | 20-06-30 |
Comptroller/Controller/Auditor | 35 | 22-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Dov Goldstein
BRD | Director/Board Member | 56 | 20-12-31 |
Eric Richman
BRD | Director/Board Member | 63 | 20-06-30 |
Matthias Alder
CEO | Chief Executive Officer | 59 | 21-10-18 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 2.51 | -1.18% | 106,802 |
24-05-09 | 2.54 | -5.22% | 239,414 |
24-05-08 | 2.68 | -7.59% | 202,533 |
24-05-07 | 2.9 | +1.75% | 164,588 |
24-05-06 | 2.85 | -3.72% | 131,742 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-23.12% | 45.31M | |
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- GANX Stock